Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H32O7S |
| Molecular Weight | 524.625 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC(COC3=CC=C4[C@H](CC(O)=O)COC4=C3)=CC=C2
InChI
InChIKey=BZCALJIHZVNMGJ-HSZRJFAPSA-N
InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.takeda.com/news/2013/20131227_6117.html | https://www.aasld.org/sites/default/files/documents/DILI/2016/IV_6_Dragan_ppt.pdf | https://www.ncbi.nlm.nih.gov/pubmed/25604916
Curator's Comment: description was created based on several sources, including:
https://www.takeda.com/news/2013/20131227_6117.html | https://www.aasld.org/sites/default/files/documents/DILI/2016/IV_6_Dragan_ppt.pdf | https://www.ncbi.nlm.nih.gov/pubmed/25604916
TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable GPR40 agonist. The drug was in Phase III clinical trials for the treatment of type 2 diabetes mellitus. Termination phase III development of TAK-875 for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4422 |
0.038 µM [Ki] | ||
Target ID: CHEMBL1697668 |
2.28 µM [IC50] | ||
Target ID: CHEMBL1743121 |
3.98 µM [IC50] | ||
Target ID: CHEMBL5748 |
2.41 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
30.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40.3 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
13.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
230 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
235.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
549.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
71.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
44.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
45.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
31.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22669289 |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FASIGLIFAM HEMIHYDRATE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. | 2011 Oct |
|
| Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. | 2011 Oct 13 |
|
| High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. | 2014 Sep 4 |
|
| Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. | 2015 Jul |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29711
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24857286
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
100000175100
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
C132780
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
GLP1W4JXAH
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
ZZ-123
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
9651
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL1829174
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
DB12491
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
1000413-72-8
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY | |||
|
DTXSID601025726
Created by
admin on Sat Dec 16 01:59:57 GMT 2023 , Edited by admin on Sat Dec 16 01:59:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
SALT/SOLVATE (PARENT)
